Arrowhead Pharmaceuticals will webcast fiscal 2020 second quarter earnings on May 7, 2020
Arrowhead Pharmaceuticals reports fiscal Q2 2020 earnings
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
Investors in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) had a good week, as its shares rose 4.9% to close at...
Arrowhead provides update related to COVID-19 efforts
Bruce Given retires from Arrowhead Pharmaceuticals
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. This report will, first...
Arrowhead announces March 2020 inducement grants
The "Lightning Round" segment of the popular Mad Money program is a viewer favorite. Callers get a chance to ask Jim Cramer about stocks they are interested in. One caller Thursday night asked about Arrowhead Pharmaceuticals : "I like this stock but it is speculative," commented Cramer.
Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...
By working together, the companies will create a unified front against two other rivals: Vertex Pharmaceuticals and Arrowhead Pharmaceuticals.
Arrowhead will present at upcoming May 2020 investor conferences
Arrowhead files to begin Phase 1/2a study of ARO-ENaC, RNAi therapeutic for Cystic Fibrosis
It hasn't been the best quarter for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders, since the share price...
The collaboration between a pharmaceutical giant and a mid-cap biotech company may have accomplished the impossible.
Thank you for joining us today to discuss Arrowhead's results for its fiscal second quarter ended March 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, Chief Medical Officer who will discuss our clinical programs; Dr. Curt Bradshaw, our Chief Scientific Officer who will discuss our discovery, platform development and manufacturing efforts; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials.
Q2 2020 Arrowhead Pharmaceuticals Inc Earnings Call
NEW YORK, March 18, 2020 -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of comScore,.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
A leading company in the field of gene silencing is on track to develop several breakthrough therapies.